Promoting Role of Pentraxin-3 in Esophageal Squamous Cell Carcinoma

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2022 Mar 23

PMID 35317523

Authors

Zhirui Fan

Yuanyuan Zheng

Xiaoli Li

Xiaoming Deng

Yan Ba

Kun Feng

Jin Su

Hui Wang

Zhenhe Suo

Lifeng Li

Affiliations

Soon will be listed here.

Abstract

Pentraxin 3 (PTX3) is an inflammatory molecule that is closely related to the proliferation, invasion, and metastasis of cancer. In order to explore the role of PTX3 in the occurrence and development of esophageal carcinoma (ESCA), we modified the PTX3 gene in ESCA cell lines to obtain the model of gene knockout and overexpression and studied cell proliferation, cycle, apoptosis, migration ability, energy metabolism, and sensitivity to chemotherapy and radiotherapy. We observed the increase in cell proliferation, cycle, apoptosis, migration ability, and sensitivity to chemotherapy and radiotherapy in the PTX3 knockout model, while in the PTX3 overexpression model, these phenomena were significantly reduced. Knockout of the PTX3 also resulted in decreased cell glycolysis and increased oxidative phosphorylation, which is consistent with other findings that PTX3 affects the tumorigenic ability of cells and their sensitivity to docetaxel. In ESCA, SOX9 directly regulates the expression of PTX3, while human leukocyte antigen (HLA)-system-related genes are significantly up-regulated when lacking PTX3. These results indicate that SOX9 may play a crucial role in regulating PTX3 and affecting the HLA system in ESCA.

Citing Articles

CCR7 in esophageal squamous cell carcinoma: an identification from single-cell and bulk transcriptome sequencing.

Yu Y, Zhao Q, Cui H, Song L Discov Oncol. 2025; 16(1):183.

PMID: 39953263 PMC: 11828771. DOI: 10.1007/s12672-025-01927-3.

Integrative Analysis and Validation of a Cancer-associated Fibroblasts Senescence-related Signature for Risk Stratification and Therapeutic Prediction in Esophageal Squamous Cell Carcinoma.

Zhang H, Hong K, Song Q, Zhu B, Wu G, Yu B J Cancer. 2024; 15(17):5742-5761.

PMID: 39308671 PMC: 11414623. DOI: 10.7150/jca.100430.

PTX3 promotes breast cancer cell proliferation and metastasis by regulating PKCζbreast cancer, pentraxin 3, protein kinase Cζ, proliferation, metastasis.

Wu J, Yang R, Ge H, Zhu Y, Liu S Exp Ther Med. 2024; 27(3):124.

PMID: 38410189 PMC: 10895465. DOI: 10.3892/etm.2024.12412.

The Role of Pentraxin 3 in Gastrointestinal Cancers.

Zajkowska M, Mroczko B Cancers (Basel). 2023; 15(24).

PMID: 38136377 PMC: 10741769. DOI: 10.3390/cancers15245832.

Organokines in COVID-19: A Systematic Review.

Barbalho S, Minniti G, Miola V, Dos Santos Haber J, Cincotto Dos Santos Bueno P, Santos de Argollo Haber L Cells. 2023; 12(10).

PMID: 37408184 PMC: 10216619. DOI: 10.3390/cells12101349.

References

Song T, Wang C, Guo C, Liu Q, Zheng X . Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer. 2018; 9(15):2650-2658. PMC: 6072810. DOI: 10.7150/jca.25188. View

Fan Z, Li L, Li X, Zhang M, Dou M, Zhao J . Anti-senescence role of heterozygous fumarate hydratase gene knockout in rat lung fibroblasts . Aging (Albany NY). 2019; 11(2):573-589. PMC: 6366963. DOI: 10.18632/aging.101761. View

Senderowicz A . Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr Opin Cell Biol. 2004; 16(6):670-8. DOI: 10.1016/j.ceb.2004.09.014. View

Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P . PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015; 160(4):700-714. DOI: 10.1016/j.cell.2015.01.004. View

Garlanda C, Bottazzi B, Bastone A, Mantovani A . Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005; 23:337-66. DOI: 10.1146/annurev.immunol.23.021704.115756. View

Liu C, Yao Y, Wang W . Pentraxin-3 as a prognostic marker in patients with small-cell lung cancer. Med Oncol. 2014; 31(10):207. DOI: 10.1007/s12032-014-0207-1. View

Inforzato A, Doni A, Barajon I, Leone R, Garlanda C, Bottazzi B . PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin Immunol. 2013; 25(1):79-85. DOI: 10.1016/j.smim.2013.05.002. View

Accolla R, Lombardo L, Abdallah R, Raval G, Forlani G, Tosi G . Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State. Front Oncol. 2014; 4:32. PMC: 3927100. DOI: 10.3389/fonc.2014.00032. View

Larsimont J, Youssef K, Sanchez-Danes A, Sukumaran V, Defrance M, Delatte B . Sox9 Controls Self-Renewal of Oncogene Targeted Cells and Links Tumor Initiation and Invasion. Cell Stem Cell. 2015; 17(1):60-73. DOI: 10.1016/j.stem.2015.05.008. View

10.

Evan G, Vousden K . Proliferation, cell cycle and apoptosis in cancer. Nature. 2001; 411(6835):342-8. DOI: 10.1038/35077213. View

11.

Locatelli M, Ferrero S, Boneschi F, Boiocchi L, Zavanone M, Maria Gaini S . The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol. 2013; 260(1-2):99-106. DOI: 10.1016/j.jneuroim.2013.04.009. View

12.

Rudolph M, Stanfield R, Wilson I . How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006; 24:419-66. DOI: 10.1146/annurev.immunol.23.021704.115658. View

13.

Wallace D . Mitochondria and cancer. Nat Rev Cancer. 2012; 12(10):685-98. PMC: 4371788. DOI: 10.1038/nrc3365. View

14.

Moss S, Blaser M . Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005; 2(2):90-7. DOI: 10.1038/ncponc0081. View

15.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

16.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

17.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

18.

Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C . The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016; 64(6):1416-27. PMC: 5414834. DOI: 10.1016/j.jhep.2016.02.029. View

19.

Willeke F, Assad A, Findeisen P, Schromm E, Grobholz R, von Gerstenbergk B . Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer. 2006; 42(15):2639-46. DOI: 10.1016/j.ejca.2006.05.035. View

20.

Stallone G, Cormio L, Netti G, Infante B, Selvaggio O, Di Fino G . Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res. 2014; 74(16):4230-8. DOI: 10.1158/0008-5472.CAN-14-0369. View